STOCK TITAN
  1. Home
  2. News
  3. VRDN

Viridian Therapeutics Inc - VRDN STOCK NEWS

Welcome to our dedicated news page for Viridian Therapeutics (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viridian Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viridian Therapeutics's position in the market.

News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Viridian Therapeutics, Inc. announced the approval of non-qualified stock options for new employees. The Inducement Grants consist of 102,000 shares of common stock, granted outside the company's Equity Incentive Plan. The options have an exercise price equal to the closing price on the Grant Date and will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Viridian Therapeutics (VRDN) announces the approval of non-qualified stock options for new employees, totaling 62,000 shares, granted as an inducement for joining the company. The options will vest over a four-year period, aligning with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
none
-
News
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on March 11. The event will focus on discovering and developing medicines for serious and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
conferences
News
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported recent business highlights and financial results for Q4 and full year 2023. They anticipate Phase 3 clinical data readouts for VRDN-001 in mid-year 2024 and VRDN-003 pivotal program in thyroid eye disease to start mid-year 2024. The company raised $150 million in gross proceeds from a public offering in January 2024, extending their operating runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
earnings
-
News
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
Rhea-AI Summary
Viridian Therapeutics appoints Jennifer Tousignant as Chief Legal Officer and grants her 290,000 stock options. Ms. Tousignant brings extensive experience from Sana Biotechnology, Xilio Therapeutics, and TESARO, Inc. The company aims to develop best-in-class medicines for thyroid eye disease and anti-neonatal Fc receptor portfolios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
management
-
News
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Viridian Therapeutics, Inc. announced the approval of a non-qualified stock options grant to an employee to purchase up to 30,000 shares of the company's common stock. The grant was made as an inducement for the individual entering into employment with Viridian and will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
none
News
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. The company is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. Additionally, they have granted the underwriters a 30-day option to purchase an additional 1,071,428 shares of common stock. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
offering
-
News
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced an underwritten public offering of shares of its common stock and Series B preferred stock. The company intends to use the proceeds for clinical development programs, working capital, and general corporate purposes. Jefferies and Leerink Partners are acting as joint lead book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
offering
-
News
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
Rhea-AI Summary
Viridian Therapeutics, a biotechnology company (NASDAQ: VRDN), announced plans for clinical trials for thyroid eye disease treatments and progress on FcRn portfolio at the 42nd Annual J.P. Morgan Healthcare Conference. Key updates include VRDN-001 Phase 3 trials for active and chronic TED, VRDN-003 pivotal study, and VRDN-006 IND anticipated by year-end 2024. Dr. Thomas Ciulla promoted to Chief Medical Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
conferences
News
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Viridian Therapeutics, Inc. (VRDN) will present at the 42nd Annual J.P. Morgan Healthcare Conference, discussing corporate priorities and potential best-in-class medicines for serious and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
Stock VRDN logo
Viridian Therapeutics Inc

Nasdaq:VRDN

VRDN Rankings

#2463 Ranked by Market Cap
#4219 Ranked by Stock Gains
N/A Ranked by Dividends

VRDN Stock Data

997.38M
47.94M
1.02%
100.99%
15.09%
Medical Laboratories
Health Care and Social Assistance
Link
US
Boulder

About VRDN

miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research